(Q38549680)

English

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

scientific article published on 17 July 2015

Statements

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy (English)
Rajeshwari Sridhara
Tiffany K Ricks
Anne Marie Russell
Gaetan Ladouceur
Rajesh Venugopal

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit